Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

Conclusions Volasertib had a manageable safety profile up to the MTD determined as 300 mg. Exposure to volasertib and its metabolite increased with increasing doses. The safety profile of volasertib in Japanese patients is comparable with those previously obtained in Caucasian patients. These data support enrollment of Japanese patients in global clinical trials without dose modification.

http://link.springer.com/10.1007/s10637-015-0300-0

Source: Investigational New Drugs - December 2, 2015 Category: Drugs & Pharmacology Source Type: research